Business Wire

1. New $500 Million Gene Therapy Drug Manufacturing Facility Announced By Pfizer (Sanford NC) 8/21/2019

   Pfizer announced today an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support Pfizer’s continuing investment in gene therapy research and development, similar to Pfizer’s Chapel Hill and Kit Creek, North Carolina research and development sites. This facility would expand the company’s presence in North Carolina, where there are currently more than 3,600 Pfizer colleagues, including 650 in

2. Paratek Pharmaceuticals Strengthens Senior Leadership Team 6/4/2015

   Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) today announced the addition of two experienced pharmaceutical executives to the company's senior leadership team to meet the company's growing needs as it advances the development program for its lead investigational antibiotic, omadacycline, and as it expands the company's pre-commercialization capabilities.

3. DCAT Announces Sharp Sourcing 2015 6/2/2015

   The Drug, Chemical & Associated Technologies Association (DCAT) announces DCAT Sharp Sourcing 2015, a conference and networking event for pharmaceutical, biopharmaceutical companies and suppliers in the pharmaceutical manufacturing value chain. 

4. Third Annual Medical Pharmacy Trend Report Illuminates Hidden Healthcare Costs 2/25/2013

   Industry reporting on specialty pharmaceuticals has historically left out medications covered and paid for under the medical benefit.

   This is the only detailed drug trend report available for those medicines administered by providers and billed under the medical benefit.

   Specialty drug costs increased 16 percent for the top 25 therapies.

5. Wingspan Adds ICON As eTMF Client 11/20/2012

   ICON Selects Wingspan eTMF as Its Preferred System in Its Efforts towards Paperless Clinical Trials.

6. FDA Approval For Use Of Sulfur Colloid Injection To Locate Lymph Nodes In Malignant Melanoma Patients 8/16/2012

   Pharmalucence, Inc. has received FDA approval expanding the indication for use of its Sulfur Colloid Injection (SCI) to include localization of lymph nodes in malignant melanoma patients.

7. IRIS International Selects ThingWorx For Next-Generation Remote Service And Support Of Medical Devices 8/16/2012

   IRIS International, Inc. is using the ThingWorx connected application platform to build its next-generation remote service management platform. The platform will enhance IRIS’ innovative iCARE™ (IRIS’ Customer Appreciation and Relationship Experience) program with high-value remote service, monitoring, and automation.

8. DSP Clinical President And Founder Darlene Panzitta Named To The PharmaVOICE 100 List Of The Most Influential People In Life Sciences Industries 8/13/2012

   Darlene Panzitta, President and Founder of DSP Clinical, is among this year's PharmaVOICE 100 List of the most influential people in lifes sciences industries.

9. Edimer Receives FDA Fast Track Designation For Lead Compound EDI200 6/14/2012

   Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder, X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), recently announced the receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for EDI200, the company’s novel, proprietary, recombinant protein.

10. Ironwood And Forest Announce FDA Has Extended The Review Period For Linaclotide To September 2012 4/24/2012

    Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) and Forest Laboratories, Inc. (NYSE: FRX) today announced that the U.S. Food and Drug Administration (FDA) notified the companies that it will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for linaclotide for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation (CC).